Centre National De La Recherche Scientifique

Zentaris Gmbh

University of Montpellier I

University of Montpellier Ii

Université Paris Descartes

Université De Rennes 1

Centre Nationale De La Recherche Scientifique

Aeterna Zentaris Gmbh

Le Centre National De La Recherche Scientifique

Æterna Zentaris Gmbh

Luc Demange

Jean Martinez

Jean-Alain Fehrentz

Aline Moulin

Daniel Perrissoud

Damien Boeglin

Laurent Meijer

Herve Galons

Nassima Oumata

Karima Bettayeb

The present invention provides novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular growth retardation, cachexia, short-, medium- and/or long term regulation of energy balance; short-, medium- and/or long term regulation (stimulation and/or inhibition) of food intake; adipogenesis, adiposity and/or obesity; body weight gain and/or reduction; diabetes, diabetes type I, diabetes type II, tumor cell proliferation; inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and/or gastrectomy (ghrelin replacement therapy).

Triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors

The invention relates to trisubstituted or tetrasubstituted imidazo[4,5b]pyridines, to their uses as well as to a process for manufacturing them. The compounds of the invention are imidazo[4,5b]pyridines. The first general synthesis of 3,5,7 imidazo[4,5b]pyridines is disclosed in the description. The invention founds application, in particular, in the pharmaceutical field.

Perharidines as CDK inhibitors

Growing community of inventors

Orsay, France

Luc Demange